Modulators of antiestrogen pharmacology
AssigneeCase Western Reserve University
InventorsMonica Montano, Amelia Sutton
Life of this patent
Estimating the term…
Abstract
A protein, designated ERCoA3 is provided. The ERCoA3 protein interacts with the estrogen receptor and the progesterone receptor and causes activation of these receptors is provided. Also provided are polynucleotides which encode ERCoA3 or block translation of the mRNA which encodes ERCoA3. Antibiodies that bind to one or more epitopes in the human ERCoA3 protein are provided. The present invention also relates to methods of inhibiting or reducing tamoxifen or estrogen induced proliferation of cancer cells, particularly breast cancer cells, endometrial cancer cells and uterine cancer cells. The method comprises reducing the activity or levels of ERCoA3 in such.
Claims7
An isolated polypeptide comprising an amino acid sequence having at least 95% identity to the amino acid sequence set forth in SEQ ID NO:
- 2, wherein said isolated polypeptide binds antagonist-bound estrogen receptor-α, agonist-bound estrogen receptor-α or progesterone receptor β, and wherein the differences between the amino acid sequence of the polypeptide and SEQ ID NO:
- 2 are due to conservative amino acid substitutions.
An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
- 2.
An isolated polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.